98%
921
2 minutes
20
Objectives: We prospectively compared the postvaccination immunity to messenger ribonucleic acid BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine of our pediatric patients over 12 years old with inflammatory bowel disease (IBD) to that of healthy controls and looked for predictors of its robustness.
Methods: Anti-receptor binding domain, anti-spike S2, and anti-nucleocapsid immunoglobin-G (IgG) and immunoglobin-A levels were measured in 139 pediatric patients with IBD [65 fully vaccinated (2 doses), median age 16.3, interquartile range (IQR) 15.2-17.8 years, median time from vaccination (IQR) 61.0 (42.0-80.0) days] and 1744 controls (46, 37-57 years) using microblot array.
Results: All IBD and control patients developed positive anti-receptor binding domain IgG antibodies at comparable titers. The proportion of observations with positive anti-spike S2 IgG was higher in patients with IBD than in controls [63% vs 21%, odds ratio 2.99 (1.51-5.90)], as was its titer [median (IQR) 485 (92-922) vs 79 [33-180] IU/mL]. Anti-receptor binding domain and anti-spike S2 IgG levels were associated with IBD status. We found an association between anti-spike S2 IgG levels and time since vaccination (β -4.85, 95% CI -7.14 to 2.71, P = 0.0001), history of SARS-CoV-2 polymerase chain reaction positivity (206.76, 95% CI 39.93-374.05, P = 0.0213), and anti-tumor necrosis factor treatment (-239.68, 95% CI -396.44-83.55, P = 0.0047). Forty-three percent of patients reported vaccination side effects (mostly mild). Forty-six percent of observations with positive anti-nucleocapsid IgG had a history of SARS-CoV-2 infection.
Conclusions: Patients with IBD produced higher levels of postvaccination anti-spike S2 antibodies than controls. Previous SARS-CoV-2 infection is associated with higher production of postvaccination antibodies and anti-tumor necrosis factor treatment with lower production.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847686 | PMC |
http://dx.doi.org/10.1097/MPG.0000000000003661 | DOI Listing |
Clin Infect Dis
August 2025
Department of Pulmonary and Infectious Diseases, Copenhagen University Hospital, North Zealand, Hillerød, Denmark.
Background: Co-administering vaccines can effectively enhance vaccination uptake in adults. Despite the potential benefits, there is limited data supporting this practice. We investigated the immunogenicity and safety of co-administering COVID-19 mRNA, Influenza, and Pneumococcal (PPSV23) vaccines in adults.
View Article and Find Full Text PDFFront Immunol
August 2025
Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing, China.
Background: Inactivated COVID-19 vaccines exhibit more rapid declines in antibody levels than other vaccine platforms, likely owing to transient antigen exposure and limited germinal center persistence. Moreover, although homologous boosting effectively restores humoral immunity, concerns persist regarding potential T cell exhaustion with repeated antigen exposure. We evaluated the effectiveness of delayed homologous CoronaVac booster immunization in reactivating immune memory.
View Article and Find Full Text PDFNat Struct Mol Biol
July 2025
School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia.
Nipah virus (NiV) and Hendra virus (HeV) are highly pathogenic henipaviruses without approved human vaccines or therapies. Here, we report on a highly potent bispecific therapeutic that combines an anti-fusion glycoprotein nanobody with an anti-receptor-binding glycoprotein (RBP) antibody to deliver a dual-targeting biologic that is resistant to viral escape. We show that the nanobody, DS90, engages a unique, conserved site within the fusion glycoprotein of NiV and HeV and provides neutralization and complete protection from NiV disease.
View Article and Find Full Text PDFMethods Mol Biol
July 2025
Laboratory of Chemical Biology and Signal Transduction, The Rockefeller University, New York, NY, USA.
We describe a methodology to map epitopes of monoclonal antibodies (mAbs) that bind to G protein-coupled receptors (GPCRs). The method involves using genetic code expansion technology to introduce a non-canonical amino acid (ncAA) residue into an expressed GPCR that can serve as a photo-activatable cross-linkers in mammalian cells in culture. Interaction sites between the engineered receptor variants and the cognate mAb are mapped by determining which of the p-azido-L-phenylalanine (azF) or p-benzoyl-L-phenylalanine (BzF) residues cross-link to the mAb upon ultraviolet (UV) irradiation.
View Article and Find Full Text PDFBackground: The COVID-19 pandemic necessitated robust vaccination strategies, including booster doses to sustain immunity against SARS-CoV-2. The comparative immunogenicity of homologous (same vaccine type) versus heterologous (different vaccine types) booster regimens remains understudied, particularly in diverse settings. This study assesses anti-receptor binding domain (RBD) IgG antibody responses to these regimens in Bangladesh.
View Article and Find Full Text PDF